For the Inventor, By the Inventor

Enter assignee name

Wilmington, DE, United States of America

Incyte Holdings Corporation

USPTO Granted Patents = 151

% Expired Patents = 4.0

CIPO Patents = 12

EPO Patents = 61

Trademarks = 26

Forward Citations = 2,436

Loading Chart...

Loading Chart...

74 inventors (with patents filed for the assignee):

Yun-Long Li (46 out of 96 patents)

Andrew Paul Combs (46 out of 129 patents)

Wenqing Yao (42 out of 228 patents)

4. James David Rodgers (30 out of 86 patents)

5. Jincong Zhuo (28 out of 76 patents)

6. Chunhong He (28 out of 73 patents)

7. Richard B Sparks (27 out of 64 patents)

8. Eddy W Yue (25 out of 70 patents)

9. Thomas P Maduskuie, Jr (21 out of 51 patents)

10. Song Mei (20 out of 42 patents)

11. Brian Walter Metcalf (17 out of 87 patents)

12. Jiacheng Zhou (16 out of 86 patents)

13. Meizhong Xu (16 out of 40 patents)

14. Colin Zhang (16 out of 45 patents)

15. Wenyu Zhu (15 out of 45 patents)

Core Competencies:

JAK Inhibitors

Topical Formulations

Sustained Release

PI3K Inhibitors

FGFR Inhibitors

PIM Kinase Inhibitors

BET Protein Inhibitors

Indoleamine 2,3-Dioxygenase

Tricyclic Compounds

Bicyclic Heterocycles

Pyrazole Derivatives

151 patents: Sort by Forward Citations

1. 12622908 - Topical formulation for a JAK inhibitor (2026-05-12),

2. 12564593 - Topical formulation for a JAK inhibitor (2026-03-03),

3. 12544381 - Topical formulation for JAK inhibitor (2026-02-10),

4. 12534463 - SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS (2026-01-27),

5. 12427154 - Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2025-09-30),

6. 12247030 - Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine (2025-03-11),

7. 12247020 - Bipyrazole derivatives as JAK inhibitors (2025-03-11),

8. 12227502 - 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins (2025-02-18),

9. 12226419 - Topical formulation for a JAK inhibitor (2025-02-18),

10. 12201636 - Heterocyclylamines as PI3K inhibitors (2025-01-21),

11. 12152033 - Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders (2024-11-26),

12. 12151026 - Sustained release dosage forms for a JAK1 inhibitor (2024-11-26),

13. 12084449 - Imidazotriazines and imidazopyrimidines as kinase inhibitors (2024-09-10),

14. 12024522 - Salts and processes of preparing a PI3K inhibitor (2024-07-02),

15. 11999751 - Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors (2024-06-04),

Company Overview

Incyte Holdings Corporation, headquartered in Wilmington, Delaware, is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics. The company specializes in JAK inhibitors, which play a crucial role in treating various inflammatory and oncological conditions. Incyte's research extends to topical formulations and sustained release technologies, as well as other targeted therapies including PI3K, FGFR, PIM kinase, and BET protein inhibitors, positioning it as a leader in advancing precision medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

151 Patents

#44 in Wilmington, DE

#55 in Delaware

#2,607 in US

#5,409 in the World

Wilmington, DE, United States of America

Incyte Holdings Corporation

Forward Citations = 2,436

74 inventors:

Yun-Long Li (46 out of 96 patents)

Andrew Paul Combs (46 out of 129 patents)

Wenqing Yao (42 out of 228 patents)

4. James David Rodgers (30 out of 86 patents)

5. Jincong Zhuo (28 out of 76 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Incyte Holdings Corporation. Retrieved from https://idiyas.com/company/incyte-holdings

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…